Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease
1. Clinical remission at 52 weeks was similar between ustekinumab and adalimumab. 2. Patient-reported outcomes of stool frequency and abdominal ...
Tag: inflammatory bowel disease (IBD)
Subcutaneous risankizumab maintenance therapy superior to placebo for moderate-severe Crohn’s disease
1. Compared to a placebo (withdrawal) group, patients maintained on subcutaneous risankizumab had greater rates of clinical remission. 2. Adverse ...
Risankizumab induction therapy is effective for moderate-to-severe Crohn’s disease
1. The risankizumab group showed greater clinical remission and endoscopic response rates compared to placebo across the ADVANCE and MOTIVATE ...
Filgotinib effectively induces and maintains clinical remission in patients with ulcerative colitis
1. At weeks 10 and 58, more patients in the filgotinib 200 mg group experienced clinical remission compared with the ...
Non-invasive clinical tool rules out inflammatory bowel disease in children with non-bloody diarrhea
1. In children with chronic, non-bloody diarrhea and abdominal pain, a clinical prediction tool using symptoms, C-reactive protein (CRP), hemoglobin, ...
Quick Take: Association of Childhood-Onset Inflammatory Bowel Disease With Risk of Psychiatric Disorders and Suicide Attempt
Childhood-onset inflammatory bowel disease (IBD) typically has a more severe course than adult-onset IBD, and has been found to be ...
2 Minute Medicine Rewind August 26, 2019
Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis Diagnosing multiple sclerosis (MS) is challenging, ...
